CA1312082C - Use of hydroquinolines for the treatment of cerebrovascular disorders - Google Patents

Use of hydroquinolines for the treatment of cerebrovascular disorders

Info

Publication number: CA1312082C
Authority: CA; Canada
Prior art keywords: oxo; bromo; pyrrolidinyl; compound; formula
Prior art date: 1985-07-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA 514877

Other languages

English (en)

French (fr)

Inventor

Geoffrey Stemp

John Morris Evans

Charles David Nicholson

Dieter Angersbach

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Beecham Wuelfing GmbH and Co KG

Beecham Group PLC

Original Assignee

Beecham Wuelfing GmbH and Co KG

Beecham Group PLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-07-31

Filing date

1986-07-29

Publication date

1992-12-29

1985-07-31 Priority claimed from GB858519306A external-priority patent/GB8519306D0/en

1985-11-13 Priority claimed from GB858527994A external-priority patent/GB8527994D0/en

1986-07-29 Application filed by Beecham Wuelfing GmbH and Co KG, Beecham Group PLC filed Critical Beecham Wuelfing GmbH and Co KG

1992-12-29 Application granted granted Critical

1992-12-29 Publication of CA1312082C publication Critical patent/CA1312082C/en

Status Expired legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims abstract description 18
208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 9
150000001875 compounds Chemical class 0.000 claims abstract description 55
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
238000000034 method Methods 0.000 claims abstract description 14
230000002490 cerebral effect Effects 0.000 claims abstract description 13
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 13
239000001257 hydrogen Substances 0.000 claims abstract description 13
125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 11
-1 polymethylene Polymers 0.000 claims abstract description 11
238000002360 preparation method Methods 0.000 claims abstract description 11
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 10
125000001246 bromo group Chemical group Br* 0.000 claims abstract description 8
125000004423 acyloxy group Chemical group 0.000 claims abstract description 6
125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 4
150000003950 cyclic amides Chemical group 0.000 claims abstract description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 6
125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims abstract 3
125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims abstract 3
239000000203 mixture Substances 0.000 claims description 18
MMKIRELCCFTFFJ-UHFFFAOYSA-N 1-(6-bromo-2,2-dimethyl-1h-quinolin-4-yl)pyrrolidin-2-one Chemical compound C=1C(C)(C)NC2=CC=C(Br)C=C2C=1N1CCCC1=O MMKIRELCCFTFFJ-UHFFFAOYSA-N 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
SKUMDJQBEBFLGF-UHFFFAOYSA-N 2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)-1h-quinoline-6-carbonitrile Chemical compound C=1C(C)(C)NC2=CC=C(C#N)C=C2C=1N1CCCC1=O SKUMDJQBEBFLGF-UHFFFAOYSA-N 0.000 claims 4
239000004615 ingredient Substances 0.000 claims 2
239000000376 reactant Substances 0.000 claims 1
239000000126 substance Substances 0.000 claims 1
238000011321 prophylaxis Methods 0.000 abstract description 9
241000124008 Mammalia Species 0.000 abstract description 6
230000000069 prophylactic effect Effects 0.000 abstract description 2
208000035475 disorder Diseases 0.000 description 13
239000003981 vehicle Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 5
125000000217 alkyl group Chemical group 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
238000012360 testing method Methods 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
238000006297 dehydration reaction Methods 0.000 description 4
229940126062 Compound A Drugs 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
230000018044 dehydration Effects 0.000 description 3
229960001760 dimethyl sulfoxide Drugs 0.000 description 3
239000000945 filler Substances 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
BCUWDJPRIHGCRN-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinolin-3-ol Chemical compound C1=CC=C2CC(O)CNC2=C1 BCUWDJPRIHGCRN-UHFFFAOYSA-N 0.000 description 2
IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
206010048962 Brain oedema Diseases 0.000 description 2
101150041968 CDC13 gene Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
CQNUVRLDYLUAJS-UHFFFAOYSA-N acetic acid;pentane Chemical compound CC(O)=O.CCCCC CQNUVRLDYLUAJS-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000001589 carboacyl group Chemical group 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
230000001054 cortical effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
CPRPKIMXLHBUGA-UHFFFAOYSA-N triethyltin Chemical compound CC[Sn](CC)CC CPRPKIMXLHBUGA-UHFFFAOYSA-N 0.000 description 2
238000009736 wetting Methods 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
241000238366 Cephalopoda Species 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
241001269524 Dura Species 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
125000005587 carbonate group Chemical group 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
PIMYDFDXAUVLON-UHFFFAOYSA-M chloro(triethyl)stannane Chemical compound CC[Sn](Cl)(CC)CC PIMYDFDXAUVLON-UHFFFAOYSA-M 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229940125833 compound 23 Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
NTGRRULFBDQNIL-UHFFFAOYSA-N copper N,N-diethylethanamine Chemical compound [Cu].C(C)N(CC)CC NTGRRULFBDQNIL-UHFFFAOYSA-N 0.000 description 1
OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
QVDYYQXUNAQSNI-UHFFFAOYSA-N ethyl acetate;pentane Chemical compound CCCCC.CCOC(C)=O QVDYYQXUNAQSNI-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000004224 protection Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229960002317 succinimide Drugs 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA 514877 1985-07-31 1986-07-29 Use of hydroquinolines for the treatment of cerebrovascular disorders Expired CA1312082C (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB8519306		1985-07-31
GB858519306A GB8519306D0 (en)	1985-07-31	1985-07-31	Treatment
GB8527994		1985-11-13
GB858527994A GB8527994D0 (en)	1985-11-13	1985-11-13	Treatment

Publications (1)

Publication Number	Publication Date
CA1312082C true CA1312082C (en)	1992-12-29

Family

ID=26289577

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 514877 Expired CA1312082C (en)	1985-07-31	1986-07-29	Use of hydroquinolines for the treatment of cerebrovascular disorders

Country Status (10)

Country	Link
EP (1)	EP0214743B1 (de)
AU (1)	AU595522B2 (de)
CA (1)	CA1312082C (de)
DE (1)	DE3688414D1 (de)
DK (1)	DK363786A (de)
ES (1)	ES2000782A6 (de)
GR (1)	GR862004B (de)
IE (1)	IE60299B1 (de)
NZ (1)	NZ217019A (de)
PT (1)	PT83111B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5404673A (en) *	1992-06-26	1995-04-11	Koito Manufacturing Co., Ltd.	Power window apparatus with safety device
RU2107499C1 (ru) *	1995-04-28	1998-03-27	Петр Иванович Бучин	Комбинированное химиотерапевтическое средство для подавления местной раневой инфекции

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0093535B1 (de) *	1982-04-28	1986-12-30	Beecham Group Plc	Chromenen und Chromanen
WO1985000602A1 (en) *	1983-07-27	1985-02-14	Beecham Group P.L.C.	Di/tetra-hydroquinolines

1986
- 1986-07-29 NZ NZ21701986A patent/NZ217019A/xx unknown
- 1986-07-29 IE IE201986A patent/IE60299B1/en not_active IP Right Cessation
- 1986-07-29 EP EP19860305804 patent/EP0214743B1/de not_active Expired - Lifetime
- 1986-07-29 AU AU60656/86A patent/AU595522B2/en not_active Expired - Fee Related
- 1986-07-29 ES ES8600684A patent/ES2000782A6/es not_active Expired
- 1986-07-29 DE DE8686305804T patent/DE3688414D1/de not_active Expired - Lifetime
- 1986-07-29 CA CA 514877 patent/CA1312082C/en not_active Expired
- 1986-07-29 GR GR862004A patent/GR862004B/el unknown
- 1986-07-30 DK DK363786A patent/DK363786A/da not_active Application Discontinuation
- 1986-07-30 PT PT8311186A patent/PT83111B/pt unknown

Also Published As

Publication number	Publication date
DE3688414D1 (de)	1993-06-17
NZ217019A (en)	1989-06-28
EP0214743A3 (en)	1990-04-11
EP0214743A2 (de)	1987-03-18
AU6065686A (en)	1987-02-05
ES2000782A6 (es)	1988-03-16
IE862019L (en)	1987-01-31
GR862004B (en)	1986-12-23
DK363786A (da)	1987-02-01
AU595522B2 (en)	1990-04-05
IE60299B1 (en)	1994-06-29
PT83111B (en)	1988-08-26
EP0214743B1 (de)	1993-05-12
PT83111A (en)	1986-08-01
DK363786D0 (da)	1986-07-30

Legal Events

Date	Code	Title	Description
2009-12-29	MKEX	Expiry

Publication	Publication Date	Title
EP0274821B1 (de)	1993-03-03	Benzopyran-Verbindungen, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5834485A (en)	1998-11-10	Quinoline sulfonamides and their therapeutic use
EP0120428B1 (de)	1990-05-23	Benzopyranisomere
IE61488B1 (en)	1994-11-02	Indole derivatives
CA2152401C (fr)	2008-08-26	Association synergisante ayant un effet antagoniste des recepteurs nk1 et nk2
KR100196985B1 (ko)	1999-06-15	피페리딘 유도체
EP0218373B1 (de)	1990-03-07	Chromanderivate und ähnliche Verbindungen mit blutdrucksenkender Wirkung
EP0238753B1 (de)	1992-01-15	N-substituierte kondensierte Polymethyleniminderivate
FR2757059A1 (fr)	1998-06-19	Nouvelle application therapeutique des derives du pyrrole
JPS6160648A (ja)	1986-03-28	２−（３，５−ジアルキル−４−ヒドロキシフエニル）インド−ル誘導体
EP0413438A1 (de)	1991-02-20	Benzopyranverbindungen
EP0214743B1 (de)	1993-05-12	Verwendung von Chinolinderivaten zur Herstellung von Medikamenten zur Behandlung von zerebralen Gefässkrankheiten und zerebraler Senilität
EP0536035A1 (de)	1993-04-07	1,8-Benzonaphthyridinderivate und antimikrobielle Zusammensetzungen
US4808619A (en)	1989-02-28	Di/tetra-hydroquinolines
US4442106A (en)	1984-04-10	Quinoline derivatives, pharmaceutical compositions containing such compounds, and methods of treating cardiovascular conditions with them
KR100251570B1 (ko)	2000-07-01	면역조절제 아자스피란
NZ241341A (en)	1993-12-23	A quinolizine derivative, preparation and pharmaceutical compositions
WO1992006956A1 (en)	1992-04-30	Indenoindole compounds
GB2192885A (en)	1988-01-27	Heterocyclic compounds
AU629076B2 (en)	1992-09-24	New piperidine derivatives the process for the preparation thereof and the pharmaceutical compositions containing them
JPH02275846A (ja)	1990-11-09	カルボン酸誘導体
EP0644187B1 (de)	1998-07-01	Antimigräne Zyklobutendion-Derivate von Tryptaminen
US4908361A (en)	1990-03-13	Tetrahydroisoquino(2,1-C)(1,3)benzodiazepines
JPS62209070A (ja)	1987-09-14	ネオリグナン誘導体
JPH06211826A (ja)	1994-08-02	セスキテルペン化合物およびそれを有効成分とする抗潰瘍剤